SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Publication/Presentation Date
1-25-2024
Abstract
BACKGROUND: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood.
OBJECTIVE: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiatedtherapy.
DESIGN: Multicenter prospective observational study.
SETTING: 34 centers in the United States.
PARTICIPANTS: 466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022.
INTERVENTIONS: SARS-CoV-2 vaccination as part of routine care.
MEASUREMENTS: We obtained blood prior to and after vaccinations at up to five time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2-specific T cell receptors (TCRs), in a subgroup.
RESULTS: Anti-S IgG and neutralizing antibody responses increased with vaccination in HCT recipients irrespective of vaccine initiation timing but were unchanged in CAR-T cell recipients initiating vaccines within 4 months. Anti-S IgG
LIMITATIONS: The majority of participants were adults and received mRNA vaccines.
CONCLUSIONS: These data support starting mRNA SARS-CoV-2 vaccination three to four months after allogeneic HCT, autologous HCT, and CAR-T cell therapy.
FUNDING: National Marrow Donor Program, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Novartis, LabCorp, American Society for Transplantation and Cellular Therapy, Adaptive Biotechnologies, and the National Institutes of Health.
Published In/Presented At
Hill, J. A., Martens, M. J., Young, J. H., Bhavsar, K., Kou, J., Chen, M., Lee, L. W., Baluch, A., Dhodapkar, M. V., Nakamura, R., Peyton, K., Howard, D. S., Ibrahim, U., Shahid, Z., Armistead, P., Westervelt, P., McCarty, J., McGuirk, J., Hamadani, M., DeWolf, S., … Perales, M. A. (2024). SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101). medRxiv : the preprint server for health sciences, 2024.01.24.24301058. https://doi.org/10.1101/2024.01.24.24301058
Disciplines
Medicine and Health Sciences
PubMedID
38343800
Department(s)
Department of Medicine
Document Type
Article